{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:14:34Z","timestamp":1786965274317,"version":"build-2736575974"},"reference-count":29,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,22]]},"DOI":"10.2967\/jnumed.124.269416","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T18:00:35Z","timestamp":1749146435000},"page":"jnumed.124.269416","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of [<sup>177<\/sup>Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials"],"prefix":"10.2967","author":[{"given":"Adrien","family":"Holzgreve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Tiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Mehrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2025060511000874000_jnumed.124.269416v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac049"},{"key":"2025060511000874000_jnumed.124.269416v1.2","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur."},{"key":"2025060511000874000_jnumed.124.269416v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"2025060511000874000_jnumed.124.269416v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025060511000874000_jnumed.124.269416v1.5","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2025060511000874000_jnumed.124.269416v1.6","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025060511000874000_jnumed.124.269416v1.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0"},{"key":"2025060511000874000_jnumed.124.269416v1.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8"},{"key":"2025060511000874000_jnumed.124.269416v1.9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study","volume":"172","author":"Pole\u00e9","year":"2022","journal-title":"Eur J Cancer."},{"key":"2025060511000874000_jnumed.124.269416v1.10","unstructured":"Hospital outpatient PPS. Addendum A. Centers for Medicare and Medicaid Services website. https:\/\/www.cms.gov\/medicare\/medicare-fee-service-payment\/hospitaloutpatientpps\/addendum-and-addendum-b-updates\/april-2024. Updated April 23, 2024. Accessed May 1, 2024."},{"key":"2025060511000874000_jnumed.124.269416v1.11","unstructured":"Medicare Part B spending by drug. Centers for Medicare and Medicaid Services website. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug\/data. Accessed May 1, 2024."},{"key":"2025060511000874000_jnumed.124.269416v1.12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/pmr.2020.0023","article-title":"Hospice or hospital: the costs of dying of cancer in the oncology care model","volume":"1","author":"Hoverman","year":"2020","journal-title":"Palliat Med Rep."},{"key":"2025060511000874000_jnumed.124.269416v1.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"2025060511000874000_jnumed.124.269416v1.14","unstructured":"CPI inflation calculator. U.S. Bureau of Labor Statistics website. https:\/\/data.bls.gov\/cgi-bin\/cpicalc.pl?cost1=0.3&year1=202206&year2=202403. Accessed May 1, 2024."},{"key":"2025060511000874000_jnumed.124.269416v1.15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3111\/13696998.2012.670175","article-title":"Elicitation of health state utilities in neuroendocrine tumours","volume":"15","author":"Swinburn","year":"2012","journal-title":"J Med Econ."},{"key":"2025060511000874000_jnumed.124.269416v1.16","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1080\/13696998.2020.1830286","article-title":"Cost-effectiveness of lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France","volume":"23","author":"Leeuwenkamp","year":"2020","journal-title":"J Med Econ."},{"key":"2025060511000874000_jnumed.124.269416v1.17","doi-asserted-by":"crossref","first-page":"1447828","DOI":"10.1080\/16549716.2018.1447828","article-title":"On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review","volume":"11","author":"Cameron","year":"2018","journal-title":"Glob Health Action."},{"key":"2025060511000874000_jnumed.124.269416v1.18","unstructured":"2020-2023 Value assessment framework. Institute for Clinical and Economic Review website. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Updated October 23, 2020. Accessed May 13, 2025."},{"key":"2025060511000874000_jnumed.124.269416v1.19","first-page":"S14","article-title":"Computer simulation of stochastic processes through model-sampling (Monte Carlo) techniques","volume":"2(suppl 1)","author":"Sheppard","year":"1969","journal-title":"FEBS Lett."},{"key":"2025060511000874000_jnumed.124.269416v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025060511000874000_jnumed.124.269416v1.21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2025060511000874000_jnumed.124.269416v1.22","doi-asserted-by":"crossref","first-page":"TPS5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","article-title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH)","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025060511000874000_jnumed.124.269416v1.23","doi-asserted-by":"crossref","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41(suppl)","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025060511000874000_jnumed.124.269416v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2025060511000874000_jnumed.124.269416v1.25","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119836204"},{"key":"2025060511000874000_jnumed.124.269416v1.26","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1002\/onco.13812","article-title":"The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors","volume":"26","author":"George","year":"2021","journal-title":"Oncologist."},{"key":"2025060511000874000_jnumed.124.269416v1.27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.033","article-title":"Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: an international double-blind, placebo-controlled randomised phase II trial\u2014Prodige 31 REMINET: an FFCD study","volume":"175","author":"Lepage","year":"2022","journal-title":"Eur J Cancer."},{"key":"2025060511000874000_jnumed.124.269416v1.28","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1007\/s00259-022-05792-y","article-title":"In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy","volume":"49","author":"Sygu\u0142a","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025060511000874000_jnumed.124.269416v1.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0947"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.269416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T18:00:38Z","timestamp":1749146438000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.269416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":29,"alternative-id":["10.2967\/jnumed.124.269416"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.269416","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]}}}